胰激肽原酶联合甲钴胺治疗2型糖尿病周围神经病变疗效观察

目的评价胰激肽原酶肠溶片联合甲钴胺注射液治疗2型糖尿病周围神经病变（DPN）的疗效。方法纳入2012年1月-12月住院的84例DPN患者,随机分为治疗组和对照组,每组42例。治疗组采用胰激肽原酶＋甲钴胺治疗,胰激肽原酶3次/d,120 U/次,口服甲钴胺1次/d,1 mg/次,静脉滴注;对照组单用甲钴胺治疗,甲钴胺静脉滴注1次/d,1 mg/次;两组均治疗14 d。结果治疗组显效22例,有效19例,无效1例;对照组显效8例,有效22例,无效12例;两组比较差异有统计学意义（P〈0.01）。两组治疗后的神经传导速度均较治疗前有所改善,治疗组治疗后的神经传导速度改善优于对照组（P〈0.01）,治疗过程中无明显不良反应。结论胰激肽原酶肠溶片联合甲钴胺注射液对DPN的疗效优于单用甲钴胺。

Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy

Objective To study the effect of combined treatment using pancreatic kinionogenase enteric-coated tab and mecobalamin injection on diabetic peripheral neuropathy（DPN） patients. Methods We collected 84 subjects with DPN who received treatment from January 2012 to December 2012 in our hospital, and we randomly divided them into treatment group（42 subjects, using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection） and control group（42 subjects, using mecobalamine only）. Subjects in the treatment group were given oral pancreatic kininogenase at 120 unit/times and 3 times/day, and methylcobalamin intravenous injection at 1 mg/day for 14 days. Subjects in the control group were only given methylcobalamin intravenous injection at 1 mg/day for 14 days. Results In the treatment group, 22 subjects showed excellent, 19 subjects effective and 1 subject ineffective outcome. In the control group, 8 subjects showed excellent, 22 effective and 12 ineffective outcome. The difference between the two groups is statistically significant（P〈0.01）. Compared with no treatment, the nerve conduction velocity in both the two groups has been improved. The improvement in the treatment group is significantly better than that of the control group（P〈0.01）, and all of them had no obvious adverse reaction during the treatment. Conclusion The combined treatment using pancreatic kinionogenase enteric-coated tab and methylcobalamin injection on DPN is better than using methylcobalamin only.